344 related articles for article (PubMed ID: 30711063)
21. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
Mital S; Nguyen HV
BMC Cancer; 2022 May; 22(1):501. PubMed ID: 35524200
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines.
Ahern CH; Shen Y
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):718-25. PubMed ID: 19258473
[TBL] [Abstract][Full Text] [Related]
24. Modeling the Cost-Effectiveness of Alternative Upper Age Limits for Breast Cancer Screening in England and Wales.
Rafia R; Brennan A; Madan J; Collins K; Reed MW; Lawrence G; Robinson T; Greenberg D; Wyld L
Value Health; 2016 Jun; 19(4):404-12. PubMed ID: 27325332
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study.
Chootipongchaivat S; Wong XY; Ten Haaf K; Hartman M; Tan KB; van Ravesteyn NT; Wee HL
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):653-660. PubMed ID: 33531436
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis.
Sankatsing VDV; Juraniec K; Grimm SE; Joore MA; Pijnappel RM; de Koning HJ; van Ravesteyn NT
Radiology; 2020 Oct; 297(1):40-48. PubMed ID: 32749212
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
28. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
29. Retrospective cost-effectiveness analysis of screening mammography.
Stout NK; Rosenberg MA; Trentham-Dietz A; Smith MA; Robinson SM; Fryback DG
J Natl Cancer Inst; 2006 Jun; 98(11):774-82. PubMed ID: 16757702
[TBL] [Abstract][Full Text] [Related]
30. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of mammographic screening strategies.
Lindfors KK; Rosenquist CJ
JAMA; 1995 Sep; 274(11):881-4. PubMed ID: 7674501
[TBL] [Abstract][Full Text] [Related]
32. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.
Stout NK; Lee SJ; Schechter CB; Kerlikowske K; Alagoz O; Berry D; Buist DS; Cevik M; Chisholm G; de Koning HJ; Huang H; Hubbard RA; Miglioretti DL; Munsell MF; Trentham-Dietz A; van Ravesteyn NT; Tosteson AN; Mandelblatt JS
J Natl Cancer Inst; 2014 Jun; 106(6):dju092. PubMed ID: 24872543
[TBL] [Abstract][Full Text] [Related]
33. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Tomosynthesis in Annual Screening Mammography.
Kalra VB; Wu X; Haas BM; Forman HP; Philpotts LE
AJR Am J Roentgenol; 2016 Nov; 207(5):1152-1155. PubMed ID: 27547861
[TBL] [Abstract][Full Text] [Related]
35. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
36. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia.
Rojnik K; Naversnik K; Mateović-Rojnik T; Primiczakelj M
Value Health; 2008; 11(2):139-48. PubMed ID: 18380626
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of risk-based breast cancer screening programme, China.
Sun L; Legood R; Sadique Z; Dos-Santos-Silva I; Yang L
Bull World Health Organ; 2018 Aug; 96(8):568-577. PubMed ID: 30104797
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
Pashayan N; Morris S; Gilbert FJ; Pharoah PDP
JAMA Oncol; 2018 Nov; 4(11):1504-1510. PubMed ID: 29978189
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]